Thu, August 26, 2010
Wed, August 25, 2010
Tue, August 24, 2010
Mon, August 23, 2010
Fri, August 20, 2010
Thu, August 19, 2010
Wed, August 18, 2010
Tue, August 17, 2010
Mon, August 16, 2010
Fri, August 13, 2010
Thu, August 12, 2010
Wed, August 11, 2010
Tue, August 10, 2010
Mon, August 9, 2010
Fri, August 6, 2010
Thu, August 5, 2010
Wed, August 4, 2010
Tue, August 3, 2010
Mon, August 2, 2010
Fri, July 30, 2010

Synergy Pharmaceuticals to Present at 2010 GHS Healthcare Conference


//health-fitness.news-articles.net/content/2010/ .. o-present-at-2010-ghs-healthcare-conference.html
Published in Health and Fitness on Thursday, August 12th 2010 at 4:45 GMT by Market Wire   Print publication without navigation


NEW YORK--([ BUSINESS WIRE ])--Synergy Pharmaceuticals, Inc. (OTC BB: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that Dr. Gary S. Jacob, the Companya™s President & Chief Executive Officer, will present at the 2010 Global Hunter Securities (GHS) Healthcare Conference to be held on Tuesday, August 17th, 2010 at the Island Hotel in Newport Beach, California. The Company is scheduled to present at 2:30 PM PDT in Cabana Room 4.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug plecanatide (formerly called SP-304) is a synthetic analog of the human gastrointestinal hormone uroguanylin, and acts by activating the guanylate cyclase C (GC-C) receptor on epithelial cells of the GI tract. Plecanatide is presently completing a Phase IIa clinical trial of SP-304 in patients to treat chronic constipation. The Company plans to release topline data from this trial in late September 2010, and initiate a Phase IIb 28-day repeated-oral-dose, placebo-controlled trial in chronic constipation patients in late 2010. More information is available at [ http://www.synergypharma.com ].


Publication Contributing Sources